Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
International Journal of Cancer|May 20, 1998
Thymic anti-tumor effectors in mice cured of lymphoma by cyclophosphamide plus TNF-alpha therapy: phenotypic and functional characterization up to 20 months after initial tumor inoculationM J Ehrke, S Verstovsek, S K Pocchiari, et al.
Leukemia|January 12, 2007
Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapyM Albitar, M Johnson, K A Do, et al.
American Journal of Clinical Oncology|February 22, 2000
Synchronous primary cancers of the breast and cervix: planning multidisciplinary primary treatment [clinico-pathological conference]S Verstovsek, C F Verschraegen, C L Edwards, et al.
International Journal of Immunopathology and Pharmacology|July 13, 2007
A novel unconventional antigen MPD5 elicits anti-tumor humoral immune responses in a subset of patients with polycythemia veraZ Xiong, E Liu, Y Yan, et al.
Leukemia|July 21, 2006
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylateE Jabbour, H Kantarjian, D Jones, et al.
Leukemia|May 24, 2003
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapyA-M Tsimberidou, H M Kantarjian, E Estey, et al.
Leukemia|September 15, 2015
A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndromeN Daver, H Kantarjian, F Ravandi, et al.
Leukemia Research|August 10, 2010
What are RBC-transfusion-dependence and -independence?R P Gale, G Barosi, T Barbui, et al.
Leukemia|January 3, 2017
Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cellsD T Saenz, W Fiskus, Y Qian, et al.
Leukemia|August 26, 2014
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)G Barosi, A Tefferi, C Besses, et al.
Pageof 5